BUZZ-Lilly's weight-loss pill data 'fell short, but not that short', BofA analysts say

Reuters08-09
BUZZ-Lilly's weight-loss pill data 'fell short, but not that short', BofA analysts say

** Shares of U.S. drugmaker Eli Lilly LLY.N fall 1% to $634.00

** BofA cuts PT on LLY to $900 from $1,000, reiterates "buy" rating

** LLY on Thursday reported late-stage data on oral weight-loss drug orforglipron that fell short of Danish rival Novo Nordisk's NOVOb.CO injectable drug Wegovy

** The data "fell short, but not that short", BofA analysts said in a client note, adding that the stock reaction was "overdone"

** Orforglipron is still a meaningful drug and doctors are unlikely to change their usage of the drug - BofA

** "Even with the new orfo data, LLY still stays in pole position in obesity" - BofA

** Brokerage estimates $10 billion in orfoglipron peak sales by 2030

** Including session moves, stock down ~18% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment